DNP vs ACAD Comparison

DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.